FOLD News and Press, Amicus Therapeutics Inc. From 11/07/22

Year-to-Date 2022 Reported Revenue Growth of 8% (16% at CER) On-Track to Deliver Full-Year 2022 Double-Digit Revenue Growth of 15-20% at CER Advancing Launch Preparation for AT-GAA in Pompe Disease Updating Full-Year 2022 Non-GAAP Operating Expense ...

Amicus Therapeutics ( NASDAQ: FOLD ) is scheduled to announce Q3 earnings results on Monday, November 7th, before market open. The consensus EPS Estimate is -$0.19 (flat Y/Y) and the consensus Revenue Estimate is $84.2M (+5.9% Y/Y). Over the last 1 year, FOLD has bea...

Summary Amicus approval gets delayed again because the FDA cannot inspect a Chinese facility. China's zero COVID policy is to blame. This may be delayed by another six months. An NDA from Amicus Therapeutics ( FOLD ) for AT-GAA (ATB200) in Pompe disease has been de...

Amicus Therapeutics ( NASDAQ: FOLD ) shares are down 6% in after-hours trading after the US FDA informed the company it was delaying making a decision on its Biologics License Application for cipaglucosidase alfa for Pompe disease. The BLA has an action date o...

FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date Company is Now Actively Engaged with the Agency to Develop Plans and Logistics for a Pre-Approv...

PHILADELPHIA, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Monday, November 7, 2022 at 8:30 a.m. ET to discuss financial results for the third quarter ended September 30, 2022. ...

PHILADELPHIA, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced four poster presentations highlighting its development program for Pompe disease will be included at the 27th International Hybrid Annual Congress of the World Muscle Society , being ...

PHILADELPHIA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced three poster presentations highlighting its development program for Pompe disease will be included at the 2022 American Association of Neuromuscular & Electrodiagnostic Medicine (A...

PHILADELPHIA, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York, NY on Wednesday, September 14, 2022 at 12:20 p.m. E.T. A ...

Summary This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion in Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total retu...